India Now Has Its Own Dialysis Machine — BEL Gets Licence to Manufacture the RxT17
Bharat Electronics Limited (BEL) has received the manufacturing and sales licence for the RxT17 — one of India’s first indigenously developed hemodialysis machines — a milestone that could meaningfully reduce what hospitals pay for dialysis equipment and cut reliance on imports.
The licence was granted by the Central Drugs Standard Control Organisation (CDSCO) after BEL cleared Class C regulatory requirements — the highest risk category for medical devices in India, demanding rigorous safety and performance validation before approval.
What Is the BEL RxT17?
The RxT17 was developed in collaboration with Renalyx and will be manufactured by BEL at its facilities. Key features:
- CE certified — meets European safety and health standards, opening export markets
- Colour touchscreen interface showing real-time operational data
- Integrated audio-visual alarms for critical conditions during dialysis sessions
- Compatible with standard consumables — works within existing hospital workflows without special supplies
- Designed for ease of operation and low-maintenance upkeep
Why This Matters for India
India faces a growing End-Stage Renal Disease (ESRD) burden, with demand for dialysis centres rising sharply across Tier 2 and Tier 3 cities — yet the country has been almost entirely dependent on imported machines from European and US manufacturers.
An indigenous, CDSCO-approved, CE-certified dialysis machine changes that equation on two fronts: it can lower procurement costs for government hospitals and private chains, and it gives India a domestically serviceable alternative that aligns with Aatmanirbhar Bharat targets in medtech.
BEL — a Defence PSU best known for radar and electronics — has been quietly expanding into medical devices. The RxT17 is the clearest signal yet that this diversification is producing market-ready products.
Source: BSE
Online Trading Institute — India’s growing platform for IPO GMP, stock market news, and trading insights is now on Google News. Click here to follow us on Google News Follow us on X (Twitter): @OTI_Labs
Disclaimer: The views and investment insights provided here are based on publicly available information and do not constitute financial advice. Readers are advised to conduct their own research or consult certified financial experts before making investment decisions.
